Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer

Shiro Urayama, Wei Zou, Kindra Brooks, Vladimir Tolstikov

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Poor outcome of pancreatic cancer necessitates development of an early diagnostic method to reduce mortality. No reliable early diagnostic test for pancreatic cancer detection has been developed and validated to date. In the current study, metabolic profiling of plasma samples from selected cancer patients and noncancerous controls was performed to seek novel metabolic biomarkers of pancreatic cancer. A comprehensive mass spectrometry based analytical platform established at the Metabo-lomics Core of the UC Davis Genome Center allowed detection of multiple compounds previously unreported in plasma from pancreatic cancer patients. It was found that selective amino acids, bile acids, and polar lipids were detected with increased or decreased levels in pancreatic cancer samples compared to controls. These findings on blood plasma levels of the relevant metabolites might be very useful clinical parameters for early diagnosis of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)613-620
Number of pages8
JournalRapid Communications in Mass Spectrometry
Volume24
Issue number5
DOIs
StatePublished - Mar 15 2010

Fingerprint

Mass spectrometry
Blood
Classifiers
Plasmas
Biomarkers
Metabolites
Bile Acids and Salts
Genes
Lipids
Amino Acids

ASJC Scopus subject areas

  • Spectroscopy
  • Analytical Chemistry
  • Organic Chemistry

Cite this

Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. / Urayama, Shiro; Zou, Wei; Brooks, Kindra; Tolstikov, Vladimir.

In: Rapid Communications in Mass Spectrometry, Vol. 24, No. 5, 15.03.2010, p. 613-620.

Research output: Contribution to journalArticle

@article{97f0967c6416463095228f7ad4a89667,
title = "Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer",
abstract = "Poor outcome of pancreatic cancer necessitates development of an early diagnostic method to reduce mortality. No reliable early diagnostic test for pancreatic cancer detection has been developed and validated to date. In the current study, metabolic profiling of plasma samples from selected cancer patients and noncancerous controls was performed to seek novel metabolic biomarkers of pancreatic cancer. A comprehensive mass spectrometry based analytical platform established at the Metabo-lomics Core of the UC Davis Genome Center allowed detection of multiple compounds previously unreported in plasma from pancreatic cancer patients. It was found that selective amino acids, bile acids, and polar lipids were detected with increased or decreased levels in pancreatic cancer samples compared to controls. These findings on blood plasma levels of the relevant metabolites might be very useful clinical parameters for early diagnosis of pancreatic cancer.",
author = "Shiro Urayama and Wei Zou and Kindra Brooks and Vladimir Tolstikov",
year = "2010",
month = "3",
day = "15",
doi = "10.1002/rcm.4420",
language = "English (US)",
volume = "24",
pages = "613--620",
journal = "Rapid Communications in Mass Spectrometry",
issn = "0951-4198",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer

AU - Urayama, Shiro

AU - Zou, Wei

AU - Brooks, Kindra

AU - Tolstikov, Vladimir

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Poor outcome of pancreatic cancer necessitates development of an early diagnostic method to reduce mortality. No reliable early diagnostic test for pancreatic cancer detection has been developed and validated to date. In the current study, metabolic profiling of plasma samples from selected cancer patients and noncancerous controls was performed to seek novel metabolic biomarkers of pancreatic cancer. A comprehensive mass spectrometry based analytical platform established at the Metabo-lomics Core of the UC Davis Genome Center allowed detection of multiple compounds previously unreported in plasma from pancreatic cancer patients. It was found that selective amino acids, bile acids, and polar lipids were detected with increased or decreased levels in pancreatic cancer samples compared to controls. These findings on blood plasma levels of the relevant metabolites might be very useful clinical parameters for early diagnosis of pancreatic cancer.

AB - Poor outcome of pancreatic cancer necessitates development of an early diagnostic method to reduce mortality. No reliable early diagnostic test for pancreatic cancer detection has been developed and validated to date. In the current study, metabolic profiling of plasma samples from selected cancer patients and noncancerous controls was performed to seek novel metabolic biomarkers of pancreatic cancer. A comprehensive mass spectrometry based analytical platform established at the Metabo-lomics Core of the UC Davis Genome Center allowed detection of multiple compounds previously unreported in plasma from pancreatic cancer patients. It was found that selective amino acids, bile acids, and polar lipids were detected with increased or decreased levels in pancreatic cancer samples compared to controls. These findings on blood plasma levels of the relevant metabolites might be very useful clinical parameters for early diagnosis of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=77049086563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77049086563&partnerID=8YFLogxK

U2 - 10.1002/rcm.4420

DO - 10.1002/rcm.4420

M3 - Article

C2 - 20143319

AN - SCOPUS:77049086563

VL - 24

SP - 613

EP - 620

JO - Rapid Communications in Mass Spectrometry

JF - Rapid Communications in Mass Spectrometry

SN - 0951-4198

IS - 5

ER -